David McDermott
MD
Director of Biologic Oncology Program
👥Biography 个人简介
David McDermott helped establish high-dose IL-2 as a curative treatment for a subset of advanced RCC patients and has been deeply involved in transitioning the field toward combination checkpoint immunotherapy. He was a principal investigator on CheckMate-016, the early study of nivolumab plus ipilimumab in RCC, and has contributed to biomarker work identifying predictors of durable IO response in RCC.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 David McDermott 的研究动态
Follow David McDermott's research updates
留下邮箱，当我们发布与 David McDermott（Beth Israel Deaconess Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment